Optain Launches with $12M in Seed Funding
Summary
Optain, a New York-based AI company that uses photos of the eye to detect and prevent early stage disease, raised $12M in Seed funding. Ascertain, a collaboration between Aegis Ventures and Northwell Holdings to develop healthcare AI companies at scale, made the investment. Led by Jeff Dunkel, CEO, Optain provides AI-enabled software and hardware products to noninvasively diagnose eye and systemic health conditions in real-time. Eyetelligence is based on the inventions of Professor Mingguang He, a leading clinician-scientist at the University of Melbourne and Centre for Eye Research Australia. The company has developed a suite of clinically validated and regulatory-approved AI products commercialized in the Australian, New Zealand, European, Japanese and Middle Eastern markets.